MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-09-2022
Clovis Oncology EBITDA per Share 2011-2026 | CLVS
Annual EBITDA per Share Clovis Oncology
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.88 | -3.33 | -6.67 | -6.32 | -5 | -7.56 | -8.3 | -4.17 | -2.89 | -2.78 | -10.2 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.88 | -10.2 | -5.38 |
Quarterly EBITDA per Share Clovis Oncology
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -0.27 | -0.39 | -0.35 | -0.41 | -0.42 | -0.49 | -0.53 | -0.67 | -0.75 | -0.98 | -1.11 | -1.67 | -1.84 | -1.69 | -1.58 | -1.84 | -1.65 | -1.48 | -1.35 | -1.26 | -1.2 | -1.25 | -1.26 | -1.74 | -1.64 | -4.07 | -2.21 | -3.83 | -2.57 | -1.99 | -1.88 | -1.59 | -1.1 | -0.93 | -0.74 | -0.9 | -0.67 | -0.72 | -0.6 | -0.81 | -0.69 | -0.6 | -0.86 | -1.26 | -10.2 | -14.2 | -6.7 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.27 | -14.2 | -1.85 |
EBITDA per Share of other stocks in the Biotechnology industry
| Issuer | EBITDA per Share | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-15.2 | - | 2.43 % | $ 254 M |  Germany |
 |
Regeneron Pharmaceuticals
REGN
|
39.4 | $ 742.1 | -1.93 % | $ 77.6 B |  USA |
 |
ARCA biopharma
ABIO
|
-5.25 | - | 1052.0 % | $ 415 M | USA |
 |
AbbVie
ABBV
|
8.95 | $ 211.9 | 0.37 % | $ 375 B | USA |
 |
Replimune Group
REPL
|
-3.2 | $ 7.26 | -3.71 % | $ 585 M | USA |
 |
AbCellera Biologics
ABCL
|
-0.67 | $ 3.28 | -2.24 % | $ 980 M |  Canada |
 |
Aeterna Zentaris
AEZS
|
-0.08 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-2.35 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-6.7 | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-1.85 | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
-2.45 | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
-4.25 | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
0.08 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.75 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-2.24 | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
-6.41 | - | -0.23 % | $ 916 M | USA |
 |
Biophytis SA
BPTS
|
-0.23 | - | -13.47 % | $ 169 M | France |
 |
Rigel Pharmaceuticals
RIGL
|
7.11 | $ 26.28 | -0.34 % | $ 473 M | USA |
 |
Aileron Therapeutics
ALRN
|
-1.99 | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
-0.92 | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
-0.09 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.22 | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-10.2 | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
-8.71 | - | -52.27 % | $ 4.45 M | USA |
 |
Avidity Biosciences
RNA
|
-5.39 | $ 13.07 | -0.23 % | $ 1.8 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.42 | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
0.14 | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
-188 | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
-1.97 | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
-1.38 | - | 4.01 % | $ 150 M | Canada |
 |
Rhythm Pharmaceuticals
RYTM
|
-2.95 | $ 77.56 | -5.31 % | $ 5.04 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
-2.69 | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
-0.12 | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-6.85 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-1.56 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-5.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-0.27 | $ 12.27 | -12.11 % | $ 1.86 B | USA |
 |
BeiGene, Ltd.
BGNE
|
0.42 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
SIGA Technologies
SIGA
|
0.34 | $ 5.36 | 7.96 % | $ 383 M | USA |
 |
Silence Therapeutics plc
SLN
|
-0.52 | $ 4.92 | -7.34 % | $ 622 M | Britain |
 |
SELLAS Life Sciences Group
SLS
|
-0.26 | $ 4.47 | -9.69 % | $ 487 M | USA |
 |
BioDelivery Sciences International
BDSI
|
0.38 | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
-2.24 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-1.82 K | - | - | $ 3.74 B | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
-1.05 | $ 1.08 | -1.38 % | $ 22.2 M | Israel |
 |
Enochian Biosciences
ENOB
|
-1.14 | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
-2.22 | - | - | $ 867 M | Germany |
 |
Summit Therapeutics
SMMT
|
-0.37 | $ 16.59 | -3.88 % | $ 12.4 B | Britain |
 |
Spruce Biosciences
SPRB
|
-47.6 | $ 62.07 | -10.19 % | $ 47.6 M | USA |